Australia's most trusted
source of pharma news
Wednesday, 20 August 2025
Posted 18 August 2025 AM
Three Big Pharmas have expanded their franchises across neurology, cardiology, and oncology.
Last week the TGA gave the go ahead to Novartis’ Zopheos - a new brand name of the company’s PBS listing multiple sclerosis treatment Kesimpta. Zopheos joins Novartis’ other brand Bonspri which was approved in 2022.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.